The hydroxamic acid derivative YPX-C-05 alleviates hypertension and vascular dysfunction through the PI3K/Akt/eNOS pathway

CONCLUSION: This study demonstrates for the first time that the novel hydroxamic acid-based HDAC inhibitor YPX-C-05 produces significant antihypertensive and vasodilatory effects through the PI3K/Akt/eNOS pathway. Our findings support the developing prospect of YPX-C-05 as a novel antihypertensive drug.PMID:38052330 | DOI:10.1016/j.vph.2023.107251

Source: Vascular Pharmacology - December 5, 2023 Category: Drugs & Pharmacology Authors: Pan-Pan Pang Hao Sun Pei-Xia Yu Wei-Min Yang Yong-Tang Zheng Xun Li Chang-Bo Zheng Source Type: research